PROSPECTUS SUPPLEMENT NO. 5
|
Filed Pursuant to Rule 424(b)(3)
|
(to prospectus dated March 19, 2021)
|
Registration No. 333-251034
|
☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
85-3584792
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
888 San Clemente Drive, Suite 400
|
|
|
Newport Beach, CA
|
|
92660
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock
|
ROCH
|
The Nasdaq Stock Market LLC
|
|
|
|
Warrants
|
ROCHW
|
The Nasdaq Stock Market LLC
|
|
|
|
Units
|
ROCHU
|
The Nasdaq Stock Market LLC
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐ |
|
|
|
|
Non-accelerated filer
|
☒ |
Smaller reporting company
|
☒ |
|
|
|
|
Emerging Growth Company
|
☒ |
• |
Item 7. Management’s discussion and analysis of financial condition and results of operations.
|
• |
Item 8. Financial Statements and Supplementary Data
|
• |
Item 9A. Controls and Procedures
|
|
2
|
||
|
|
|
|
|
ITEM 1.
|
2
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
ITEM 2.
|
4
|
|
|
|
|
|
|
ITEM 3.
|
4
|
|
|
|
|
|
|
ITEM 4.
|
4
|
|
|
|
|
|
|
5
|
||
|
|
|
|
|
ITEM 5.
|
5
|
|
|
|
|
|
|
ITEM 6.
|
5
|
|
|
|
|
|
|
ITEM 7.
|
5
|
|
|
|
|
|
|
|
9
|
|
|
|
|
|
|
ITEM 8.
|
9
|
|
|
|
|
|
|
ITEM 9.
|
9
|
|
|
|
|
|
|
|
9
|
|
|
|
|
|
|
|
9
|
|
|
|
|
|
|
10
|
||
|
|
|
|
|
ITEM 10.
|
10
|
|
|
|
|
|
|
ITEM 11.
|
14
|
|
|
|
|
|
|
ITEM 12.
|
15
|
|
|
|
|
|
|
ITEM 13.
|
16 |
|
|
|
|
|
|
ITEM 14.
|
17
|
|
|
|
|
|
|
18
|
||
|
|
|
|
|
ITEM 15.
|
18
|
|
|
|
|
|
|
ITEM 16.
|
19 |
• |
ability to complete our initial business combination;
|
• |
success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
|
• |
officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense
reimbursements;
|
• |
potential ability to obtain additional financing to complete our initial business combination;
|
• |
pool of prospective target businesses;
|
• |
the ability of our officers and directors to generate a number of potential investment opportunities;
|
• |
potential change in control if we acquire one or more target businesses for stock;
|
• |
the potential liquidity and trading of our securities;
|
• |
the lack of a market for our securities;
|
• |
use of proceeds not held in the trust account or available to us from interest income on the trust account balance; or
|
• |
financial performance following our initial public offering.
|
ITEM 1. |
BUSINESS
|
ITEM 1A. |
RISK FACTORS
|
ITEM 1B. |
UNRESOLVED STAFF COMMENTS
|
ITEM 2. |
PROPERTIES
|
ITEM 3. |
LEGAL PROCEEDINGS
|
ITEM 4. |
MINE SAFETY DISCLOSURES
|
ITEM 5. |
ITEM 6. |
ITEM 7. |
ITEM 7A. |
ITEM 8. |
ITEM 9A. |
ITEM 9B. |
ITEM 10. |
Name
|
|
Age
|
|
Position
|
Byron Roth
|
|
58
|
|
Chief Executive Officer and Chairman of the Board
|
Gordon Roth
|
|
66
|
|
Chief Financial Officer
|
Rick Hartfiel
|
|
57
|
|
Co-President
|
John Lipman
|
|
44
|
|
Chief Operating Officer and Director
|
Aaron Gurewitz
|
|
52
|
|
Co-President
|
Molly Montgomery
|
|
54
|
|
Independent Director
|
Daniel M. Friedberg
|
|
59
|
|
Independent Director
|
Adam Rothstein
|
|
49
|
|
Independent Director
|
ITEM 11. |
ITEM 12. |
Name and Address of
Beneficial Owner(1)
|
Amount and Nature of
Beneficial Ownership(2)
|
Approximate Percentage
of Outstanding
Common Stock
|
||||||
Byron Roth(3)
|
752,706
|
7.7
|
||||||
Aaron Gurewitz(4)
|
115,924
|
1.2
|
||||||
Gordon Roth(5)
|
460,183
|
4.7
|
||||||
John Lipman
|
264,365
|
2.7
|
||||||
Rick Hartfiel
|
75,533
|
*
|
||||||
Molly Montgomery
|
85,658
|
*
|
||||||
Daniel M. Friedberg(6)
|
85,658
|
*
|
||||||
Adam Rothstein
|
47,829
|
*
|
||||||
All officers and directors as a group (8 individuals)
|
1,503,226
|
15.3
|
||||||
Craig-Hallum Capital Group LLC(7)
|
321,015
|
3.3
|
||||||
Roth Capital Partners, LLC
|
384,650
|
3.9
|
||||||
BNP Paribas Asset Management UK Ltd.(8)
|
1,026,618
|
10.45
|
ITEM 13. |
ITEM 14. |
2020
|
2019
|
|||||||
Audit Fees(1)
|
$
|
190,560
|
$
|
17,500
|
||||
Audit Related Fees
|
$
|
--
|
$
|
--
|
||||
Tax Fees
|
$
|
--
|
$
|
--
|
||||
All Other Fees
|
$
|
--
|
$
|
--
|
(1)
|
Audit fees represent fees for professional services provided in connection with the audit of our financial statements and review of our quarterly financial statements and audit services provided in
connection with other statutory or regulatory filings.
|
ITEM 15. |
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
(a)
|
The following are filed with this report:
|
|
(1)
|
The financial statements listed on the Financial Statements’ Table of Contents
|
|
(2)
|
Not applicable
|
(b)
|
Exhibits
|
Exhibit No.
|
Description
|
|
1.1
|
|
Underwriting Agreement, dated May 4, 2020, by and among Registrant and Roth Capital Partners, LLC and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 1.1 to the
Current Report on Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
Merger Agreement dated November 16, 2020 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on November 16, 2020)
|
|
3.1
|
|
Amended & Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on
May 7, 2020)
|
|
Bylaws (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 27, 2020)
|
|
|
Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 16, 2020)
|
|
|
Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 16,
2020)
|
|
|
Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 16, 2020)
|
|
4.4
|
|
Warrant Agreement, dated May 4, 2020 between Continental Stock Transfer & Trust Company and the Registrant. (incorporated by reference to Exhibit 4.1 to the Current Report on
Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
Description of Securities
|
|
|
Letter Agreement, dated May 4, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to Exhibit 10.1 to the
Current Report on Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
|
Investment Management Trust Agreement, dated May 4, 2020, between Continental Stock Transfer & Trust Company and the Registrant. (incorporated by reference to Exhibit 10.2 to the
Current Report on Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
|
Stock Escrow Agreement, dated May 4, 2020, between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 10.3 to the Current Report on
Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
|
Registration Rights Agreement, dated May 4, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to
Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
|
Indemnity Agreement, dated May 4, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to Exhibit 10.5 to the
Current Report on Form 8-K filed with the Securities & Exchange Commission on May 7, 2020)
|
|
10.6+
|
|
Loan Commitment Letter, dated November 2, 2020, by and between the Registrant and CR Financial Holdings, Inc.
|
10.7+
|
|
Loan Commitment Letter, dated February 22, 2021, by and between the Registrant and CR Financial Holdings, Inc.
|
|
Form of Code of Ethics (incorporated by reference to Exhibit 14 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 16, 2020)
|
|
21+
|
|
List of Subsidiaries
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to § 302 of the Sarbanes-Oxley Act of 2002
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to § 302 of the Sarbanes-Oxley Act of 2002
|
|
|
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002
|
|
|
Form of Audit Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on March 16,
2020)
|
|
99.2
|
|
Form of Corporate Governance and Nominating Committee Charter (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-1/A filed with the Securities &
Exchange Commission on March 16, 2020)
|
99.3
|
|
Form of Compensation Committee Charter (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on
March 16, 2020)
|
101.INS
|
|
XBRL Instance Document
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
ITEM 16. |
|
ROTH CH ACQUISITION I CO.
|
Dated: June 14, 2021
|
By:
|
/s/ Michael Otworth
|
|
Name: Michael Otworth
|
|
Title: Chief Executive Officer
|
F-2
|
|
Financial Statements:
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
|
F-7 to F-21
|
December 31,
|
||||||||
(Restated)
2020 |
2019
|
|||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
200,580
|
$
|
194,970
|
||||
Prepaid expenses
|
106,439
|
—
|
||||||
Total Current Assets
|
307,019
|
194,970
|
||||||
Deferred offering costs
|
—
|
85,938
|
||||||
Marketable securities held in Trust Account
|
76,535,131
|
—
|
||||||
TOTAL ASSETS
|
$
|
76,842,150
|
$
|
280,908
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued expenses
|
$
|
727,110
|
$
|
1,564
|
||||
Accrued offering costs
|
—
|
55,938
|
||||||
Promissory note — related party
|
—
|
200,000
|
||||||
Total Current Liabilities
|
727,110
|
257,502
|
||||||
Warrant liability
|
1,624,860
|
—
|
||||||
Deferred underwriting fee payable
|
2,677,500
|
—
|
||||||
TOTAL LIABILITIES
|
5,029,470
|
257,502
|
||||||
Commitments
|
||||||||
Common stock subject to possible redemption, 6,681,267 shares at redemption value at December 31, 2020
|
66,812,670
|
—
|
||||||
Stockholders’ Equity
|
||||||||
Common stock, $0.0001 par value; 50,000,000 shares authorized; 3,146,733 and 2,156,250 shares issued and outstanding (excluding 6,681,267 and no shares subject to possible redemption) as of
December 31, 2020 and 2019, respectively (1)
|
314
|
216
|
||||||
Additional paid-in capital
|
7,334,509
|
24,784
|
||||||
Accumulated deficit
|
(2,334,813
|
)
|
(1,594
|
)
|
||||
Total Stockholders’ Equity
|
5,000,010
|
23,406
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
76,842,150
|
$
|
280,908
|
(1)
|
Included an aggregate of up to 281,250 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters at December 31, 2019 (see Note 6).
|
(Restated)
Year EndedDecember 31,
2020
|
For the
Period from
February 13,
2019
(Inception)
Through
December 31,
2019
|
|||||||
Operating and formation costs
|
$
|
1,097,684
|
$
|
1,594
|
||||
Loss from operations
|
(1,097,684
|
)
|
(1,594
|
)
|
||||
Other income (loss):
|
||||||||
Change in fair value of warrants
|
(1,248,514
|
)
|
—
|
|||||
Offering costs attributable to warrants
|
(22,152
|
)
|
—
|
|||||
Interest earned on marketable securities held in Trust Account
|
35,131
|
—
|
||||||
Net loss
|
$
|
(2,333,219
|
)
|
$
|
(1,594
|
)
|
||
Basic and diluted weighted average shares outstanding, Common stock subject to possible redemption
|
6,899,829
|
—
|
||||||
Basic and diluted net loss per share, Common stock subject to possible redemption
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
||
Basic and diluted weighted average shares outstanding, Common stock (1)
|
2,549,960
|
1,875,000
|
||||||
Basic and diluted net loss per share, Common stock
|
$
|
(0.92
|
)
|
$
|
(0.00
|
)
|
(1)
|
Excludes an aggregate of 281,250 shares subject to forfeiture at December 31, 2019 (see Note 6).
|
Common Stock
|
Additional
Paid-in
|
Accumulated
|
Total
Stockholders’
|
|||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
||||||||||||||||
Balance – February 13, 2019 (inception)
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
|||||||||||
Issuance of common stock to Initial Stockholders (1)
|
2,156,250
|
216
|
24,784
|
—
|
25,000
|
|||||||||||||||
Net loss
|
—
|
—
|
—
|
(1,594
|
)
|
(1,594
|
)
|
|||||||||||||
Balance – December 31, 2019
|
2,156,250
|
216
|
24,784
|
(1,594
|
)
|
23,406
|
||||||||||||||
Sale of 7,650,000 Units, net of underwriting discount and offering expenses
|
7,650,000
|
765
|
71,843,074
|
—
|
71,843,839
|
|||||||||||||||
Sale of 265,500 Private Units
|
265,500
|
26
|
2,278,628
|
—
|
2,278,654
|
|||||||||||||||
Forfeiture of Founder Shares
|
(243,750
|
)
|
(24
|
)
|
24
|
—
|
—
|
|||||||||||||
Common stock subject to possible redemption
|
(6,681,267
|
)
|
(668
|
)
|
(66,812,002
|
)
|
—
|
(66,812,670
|
)
|
|||||||||||
Net loss
|
—
|
—
|
—
|
(2,333,219
|
)
|
(2,333,219
|
)
|
|||||||||||||
Balance – December 31, 2020 (as restated)
|
3,146,733
|
$
|
315
|
$
|
7,334,508
|
$
|
(2,333,219
|
)
|
$
|
5,000,010
|
(1)
|
Included an aggregate of up to 281,250 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters at December 31, 2019 (see Note 6).
|
(Restated)
Year EndedDecember 31,
2020
|
For the
Period from
February 13,
2019
(Inception)
Through
December 31,
2019
|
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net loss
|
$
|
(2,333,219
|
)
|
$
|
(1,594
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Change in fair value of warrant liability
|
1,248,514
|
—
|
||||||
Offering costs attributable to warrants
|
22,152
|
—
|
||||||
Interest earned on marketable securities held in Trust Account
|
(35,131
|
)
|
—
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses
|
(106,439
|
)
|
—
|
|||||
Accounts payable and accrued expenses
|
725,546
|
1,564
|
||||||
Net cash used in operating activities
|
(478,577
|
)
|
(30
|
)
|
||||
Cash Flows from Investing Activities:
|
||||||||
Investment of cash in Trust Account
|
(76,500,000
|
)
|
—
|
|||||
Net cash used in investing activities
|
(76,500,000
|
)
|
—
|
|||||
Cash Flows from Financing Activities:
|
||||||||
Proceeds from issuance of common stock to Initial Stockholders
|
—
|
25,000
|
||||||
Proceeds from sale of Units, net of underwriting discounts paid
|
74,970,000
|
—
|
||||||
Proceeds from sale of Private Units
|
2,655,000
|
—
|
||||||
Proceeds from promissory note – related party
|
—
|
200,000
|
||||||
Repayment of promissory note – related party
|
(200,000
|
)
|
—
|
|||||
Payment of offering costs
|
(440,813
|
)
|
(30,000
|
)
|
||||
Net cash provided by financing activities
|
76,984,187
|
195,000
|
||||||
Net Change in Cash
|
5,610
|
194,970
|
||||||
Cash – Beginning of period
|
194,970
|
—
|
||||||
Cash – End of period
|
$
|
200,580
|
$
|
194,970
|
||||
Non-Cash investing and financing activities:
|
||||||||
Initial classification of common stock subject to possible redemption
|
$
|
69,123,214
|
$
|
—
|
||||
Change in value of common stock subject to possible redemption
|
$
|
(2,310,544
|
)
|
$
|
—
|
|||
Initial fair value of warrant liability
|
(376,346
|
)
|
—
|
|||||
Deferred underwriting fee payable
|
$
|
2,677,500
|
$
|
—
|
||||
Offering costs included in accrued offering costs
|
$
|
—
|
$
|
55,938
|
As Filed
|
Restatement
Adjustment |
As Restated
|
||||||||||
Consolidated Balance Sheets as of May 7, 2020
|
||||||||||||
Warrant liability
|
$
|
-
|
$
|
372,094
|
$
|
372,094
|
||||||
Ordinary shares subject to possible redemption
|
68,052,060
|
(372,094
|
)
|
67,679,966
|
||||||||
Class A ordinary shares
|
311
|
4
|
315
|
|||||||||
Additional paid-in capital
|
5,001,816
|
22,026
|
5,023,842
|
|||||||||
Accumulated deficit
|
$
|
(2,124
|
)
|
$
|
(22,030
|
)
|
$
|
(24,154
|
)
|
|||
Consolidated Balance Sheets as of June 30, 2020
|
||||||||||||
Warrant liability
|
$
|
-
|
$
|
376,346
|
$
|
376,346
|
||||||
Ordinary shares subject to possible redemption
|
69,396,260
|
(376,346
|
)
|
69,019,914
|
||||||||
Class A ordinary shares
|
289
|
3
|
292
|
|||||||||
Additional paid-in capital
|
5,105,138
|
22,149
|
5,127,287
|
|||||||||
Accumulated deficit
|
(105,417
|
)
|
(22,152
|
)
|
(127,569
|
)
|
||||||
Consolidated Balance Sheets as of September 30, 2020
|
||||||||||||
Warrant liability
|
$
|
-
|
$
|
430,110
|
$
|
430,110
|
||||||
Ordinary shares subject to possible redemption
|
69,276,060
|
(430,110
|
)
|
68,845,950
|
||||||||
Class A ordinary shares
|
290
|
5
|
295
|
|||||||||
Additional paid-in capital
|
5,225,337
|
75,911
|
5,301,248
|
|||||||||
Accumulated deficit
|
(225,626
|
)
|
(75,916
|
)
|
(301,542
|
)
|
||||||
Consolidated Balance Sheets as of December 31, 2020
|
||||||||||||
Warrant liability
|
$
|
-
|
$
|
1,624,860
|
$
|
1,624,860
|
||||||
Ordinary shares subject to possible redemption
|
68,437,530
|
(1,624,860
|
)
|
66,812,670
|
||||||||
Class A ordinary shares
|
298
|
16
|
314
|
|||||||||
Additional paid-in capital
|
6,063,859
|
1,270,650
|
7,334,509
|
|||||||||
Accumulated deficit
|
(1,064,147
|
)
|
(1,270,666
|
)
|
(2,334,813
|
)
|
As Filed
|
Restatement
Adjustment |
As Restated
|
||||||||||
Consolidated Statements of Changes in Stockholders’ Equity as of December 31, 2020
|
||||||||||||
Sales of 7,650,000 Units, net of underwriting discount and offering expenses
|
$
|
71,821,687
|
$
|
22,152
|
$
|
71,843,839
|
||||||
Sales of 265,500 Private Units
|
2,655,000
|
(376,346
|
)
|
2,278,654
|
||||||||
Common stock subject to possible redemption
|
(68,437,530
|
)
|
1,624,860
|
(66,812,670
|
)
|
|||||||
Net loss
|
(1,062,553
|
)
|
(1,270,666
|
)
|
(2,333,219
|
)
|
As Filed
|
Restatement
Adjustment
|
As Restated
|
||||||||||
Consolidated Statements of Operations for the period January 1, 2020 to December 31, 2020
|
||||||||||||
Income (loss) from change in FV of warrants
|
$
|
-
|
$
|
(1,248,514
|
)
|
$
|
(1,248,514
|
)
|
||||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Net loss
|
(1,062,553
|
)
|
(1,270,666
|
)
|
(2,333,219
|
)
|
||||||
Basic and diluted net loss per ordinary share
|
(0.42
|
)
|
(0.50
|
)
|
(0.92
|
)
|
As Filed
|
Restatement
Adjustment
|
As Restated
|
||||||||||
Consolidated Statements of Operations for the three months July 1, 2020 to September 30, 2020
|
||||||||||||
Income (loss) from change in FV of warrants
|
$
|
-
|
$
|
(53,764
|
)
|
$
|
(53,764
|
)
|
||||
Offering costs attributable to warrants
|
-
|
-
|
-
|
|||||||||
Net loss
|
(120,209
|
)
|
(53,764
|
)
|
(173,913
|
)
|
||||||
Basic and diluted net loss per ordinary share
|
(0.05
|
)
|
(0.02
|
)
|
(0.07
|
)
|
||||||
Consolidated Statements of Operations for the nine months January 1, 2020 to September 30, 2020
|
||||||||||||
Income (loss) from change in FV of warrants
|
$
|
-
|
$
|
(53,764
|
)
|
$
|
(53,764
|
)
|
||||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Net loss
|
(224,032
|
)
|
(75,916
|
)
|
(299,948
|
)
|
||||||
Basic and diluted net loss per ordinary share
|
(0.09
|
)
|
(0.03
|
)
|
(0.12
|
)
|
As Filed
|
Restatement
Adjustment |
As Restated
|
||||||||||
Consolidated Statements of Operations for the three April 1, 2020 to June 30, 2020
|
||||||||||||
Income (loss) from change in FV of warrants
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Net loss
|
(103,353
|
)
|
(22,152
|
)
|
(125,505
|
)
|
||||||
Basic and diluted net loss per ordinary share
|
(0.05
|
)
|
(0.00
|
)
|
(0.05
|
)
|
||||||
Consolidated Statements of Operations for the six months January 1, 2020 to June 30, 2020
|
||||||||||||
Income (loss) from change in FV of warrants
|
||||||||||||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Net loss
|
(103,823
|
)
|
(22,152
|
)
|
(125,975
|
)
|
||||||
Basic and diluted net loss per ordinary share
|
(0.05
|
)
|
(0.00
|
)
|
(0.05
|
)
|
As Filed
|
Restatement
Adjustment |
As Restated
|
||||||||||
Consolidated Statements of Cash Flows period from January 1, 2020 to December 31, 2020
|
||||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net loss
|
$
|
(1,062,553
|
)
|
$
|
(1,270,666
|
)
|
$
|
(2,333,219
|
)
|
|||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Change in fair value of warrant liability
|
-
|
(1,248,514
|
)
|
(1,248,514
|
)
|
|||||||
Non-Cash investing and financing activities:
|
||||||||||||
Initial measurement of warrant liability
|
-
|
(376,346
|
)
|
(376,346
|
)
|
|||||||
Initial value of Class A ordinary shares subject to possible redemption
|
69,499,560
|
(376,346
|
)
|
69,123,214
|
||||||||
Change in value of Class A ordinary shares subject to possible redemption
|
$
|
(1,062,030
|
)
|
$
|
(1,248,514
|
)
|
$
|
(2,310,544
|
)
|
|||
Consolidated Statements of Cash Flows period from January 1, 2020 to September 30, 2020
|
||||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net loss
|
$
|
(224,032
|
)
|
$
|
(75,916
|
)
|
$
|
(299,948
|
)
|
|||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Change in fair value of warrant liability
|
-
|
(53,764
|
)
|
(53,764
|
)
|
|||||||
Non-Cash investing and financing activities:
|
||||||||||||
Initial measurement of warrant liability
|
$
|
-
|
$
|
(376,346
|
)
|
$
|
(376,346
|
)
|
||||
Initial value of Class A ordinary shares subject to possible redemption
|
68,052,060
|
1,071,154
|
69,123,214
|
|||||||||
Change in value of Class A ordinary shares subject to possible redemption
|
1,224,000
|
(1,501,264
|
)
|
(277,264
|
)
|
|||||||
Consolidated Statements of Cash Flows period from Jauary 1, 2020 to June 30, 2020
|
||||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net loss
|
$
|
(103,823
|
)
|
$
|
(22,152
|
)
|
$
|
(125,975
|
)
|
|||
Offering costs attributable to warrants
|
-
|
(22,152
|
)
|
(22,152
|
)
|
|||||||
Change in fair value of warrant liability
|
-
|
-
|
-
|
|||||||||
Non-Cash investing and financing activities:
|
||||||||||||
Initial measurement of warrant liability
|
$
|
-
|
$
|
(376,346
|
)
|
$
|
(376,346
|
)
|
||||
Initial value of Class A ordinary shares subject to possible redemption
|
68,052,060
|
1,071,154
|
69,123,214
|
|||||||||
Change in value of Class A ordinary shares subject to possible redemption
|
1,344,200
|
(1,447,500
|
)
|
(103,300
|
)
|
For the year
ended
December 31,
2020
|
For the
Period
from
February 13,
2019
(Inception)
through
December 31,
2019
|
|||||||
Common stock subject to possible redemption
|
||||||||
Numerator: Earnings allocable to Common stock subject to possible redemption
|
||||||||
Interest earned on marketable securities held in Trust Account
|
$
|
35,131
|
$
|
—
|
||||
Less: interest available to be withdrawn for payment of taxes
|
(35,131
|
)
|
||||||
Net income
|
$
|
—
|
$
|
—
|
||||
Denominator: Weighted Average Common stock subject to possible redemption
|
||||||||
Basic and diluted weighted average shares outstanding
|
6,899,829
|
—
|
||||||
Basic and diluted net income per share
|
$
|
0.00
|
$
|
—
|
||||
Non-Redeemable Common Stock
|
||||||||
Numerator: Net Loss minus Net Earnings
|
||||||||
Net loss
|
$
|
(2,333,219
|
)
|
$
|
(1,594
|
)
|
||
Net income allocable to Common stock subject to possible redemption
|
—
|
—
|
||||||
Non-Redeemable Net Loss
|
$
|
(2,333,219
|
)
|
$
|
(1,594
|
)
|
||
Denominator: Weighted Average Non-Redeemable Common Stock
|
||||||||
Basic and diluted weighted average shares outstanding
|
2,549,960
|
1,875,000
|
||||||
Basic and diluted net loss per share
|
$
|
(0.92
|
)
|
$
|
(0.00
|
)
|
● |
in whole and not in part;
|
● |
at a price of $0.01 per warrant;
|
● |
upon not less than 30 days’ prior written notice of redemption;
|
● |
if, and only if, the reported last sale price of the shares of common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30
trading day period ending on the third business day prior to the notice of redemption to warrant holders; and
|
● |
if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying the warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing
each day thereafter until the date of redemption.
|
2020 |
||||
Expected annual dividend yield
|
—
|
%
|
||
Expected volatility
|
29.4 – 45.6
|
%
|
||
Risk-free rate of return
|
0.34 – 0.39
|
%
|
||
Expected option term (years)
|
5.21 - 5.50
|
Fair value
(Level 3)
|
||||
Balance at May 7, 2020 (inception)
|
$
|
376,346
|
||
Change in fair value
|
1,248,514
|
|||
Balance at December 31, 2020
|
$
|
1,624,860
|
As of December 31,
|
||||||||
2020
|
2019
|
|||||||
Deferred tax assets
|
||||||||
Net operating loss carryforward
|
$
|
81,301
|
$
|
335
|
||||
Total deferred tax assets
|
81,301
|
335
|
||||||
Valuation Allowance
|
(81,301
|
)
|
(335
|
)
|
||||
Deferred tax assets, net valuation allowance
|
$
|
—
|
$
|
—
|
December 31,
|
For the
period from
February 13,
2019
(Inception)
Through
December 31,
|
|||||||
2020
|
2019
|
|||||||
Federal
|
||||||||
Current
|
$
|
—
|
$
|
—
|
||||
Deferred
|
(80,966
|
)
|
(335
|
)
|
||||
State and Local
|
||||||||
Current
|
—
|
—
|
||||||
Deferred
|
—
|
—
|
||||||
Change in valuation allowance
|
80,966
|
335
|
||||||
Income tax provision
|
$
|
—
|
$
|
—
|
As of December 31,
|
||||||||
2020
|
2019
|
|||||||
Statutory federal income tax rate
|
21.0
|
%
|
21.0
|
%
|
||||
Change in Fair Value of Private Warrant liability
|
11.4
|
% |
0.0 |
% |
||||
Business combination expenses
|
(6.1
|
)%
|
0.0
|
%
|
||||
Valuation allowance
|
(26.3
|
)%
|
(21.0
|
)%
|
||||
Income tax provision
|
0.0
|
%
|
0.0
|
%
|